CA2736877A1 - Clean genome bactofection - Google Patents

Clean genome bactofection Download PDF

Info

Publication number
CA2736877A1
CA2736877A1 CA2736877A CA2736877A CA2736877A1 CA 2736877 A1 CA2736877 A1 CA 2736877A1 CA 2736877 A CA2736877 A CA 2736877A CA 2736877 A CA2736877 A CA 2736877A CA 2736877 A1 CA2736877 A1 CA 2736877A1
Authority
CA
Canada
Prior art keywords
cell
gene
bacterium
replication
origin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2736877A
Other languages
English (en)
French (fr)
Inventor
Frederick R. Blattner
Val Burland
Charles Landry
Nian-Qing Shi
Buffy Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scarab Genomics LLC
Original Assignee
Scarab Genomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scarab Genomics LLC filed Critical Scarab Genomics LLC
Publication of CA2736877A1 publication Critical patent/CA2736877A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2736877A 2008-09-12 2009-09-14 Clean genome bactofection Abandoned CA2736877A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9664908P 2008-09-12 2008-09-12
US61/096,649 2008-09-12
PCT/US2009/056829 WO2010030986A2 (en) 2008-09-12 2009-09-14 Clean genome bactofection

Publications (1)

Publication Number Publication Date
CA2736877A1 true CA2736877A1 (en) 2010-03-18

Family

ID=41328762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736877A Abandoned CA2736877A1 (en) 2008-09-12 2009-09-14 Clean genome bactofection

Country Status (5)

Country Link
US (1) US20110165680A1 (https=)
EP (1) EP2344646A2 (https=)
JP (1) JP2012501680A (https=)
CA (1) CA2736877A1 (https=)
WO (1) WO2010030986A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085539A1 (en) * 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
EP2742127B1 (en) * 2011-08-12 2019-10-09 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol-2 promoter in prokaryotes
WO2013043459A1 (en) * 2011-09-22 2013-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Shigella-derived vector and methods of using the same
DK2758074T3 (da) * 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
US10196662B2 (en) * 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN109312345B (zh) * 2018-04-26 2021-07-20 广州中科蓝华生物科技有限公司 一种启动子及其应用
CN109402155A (zh) * 2018-11-12 2019-03-01 川北医学院 一种双控延迟裂解性质粒及其构建方法与应用
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
KR20220066384A (ko) * 2019-09-25 2022-05-24 카톨리에케 유니버시테이트 루벤 대형 벡터 및 고수율 제조를 위한 방법
EP4103214B1 (en) 2020-02-13 2026-04-29 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
US20240261394A1 (en) * 2020-05-11 2024-08-08 University Of Virginia Patent Foundation Compositions and methods for inducing immune responses against class i fusion protein viruses
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
AU2022286964A1 (en) * 2021-06-02 2024-01-18 Sivec Biotechnologies Llc Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells
CN117771264B (zh) * 2023-11-27 2024-06-25 山东省农业科学院畜牧兽医研究所 circHIF1α在制备抵御细菌感染的新型疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989265B2 (en) * 2002-01-23 2006-01-24 Wisconsin Alumni Research Foundation Bacteria with reduced genome
US8119365B2 (en) * 2002-01-23 2012-02-21 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
EP2543726B1 (en) * 2005-08-20 2018-10-03 Scarab Genomics, LLC Reduced genome E. coli
US8048999B2 (en) * 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
EP2049668A2 (en) * 2006-08-03 2009-04-22 Wisconsin Alumni Research Foundation Vector systems

Also Published As

Publication number Publication date
EP2344646A2 (en) 2011-07-20
WO2010030986A2 (en) 2010-03-18
US20110165680A1 (en) 2011-07-07
JP2012501680A (ja) 2012-01-26
WO2010030986A3 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
US20110165680A1 (en) Clean genome bactofection
US9556441B2 (en) Methods of transforming a Listeria
JP3976685B2 (ja) タンパク質分泌のためのＣｌｙＡ溶血素の使用
JP2001519162A (ja) 動物細胞にｒｎａを導入して発現させる方法
JP2003506007A (ja) 抗原送達用プラスミド維持系
KR20100065243A (ko) 마이코박테리움의 일렉트로포레이션 및 마이코박테리아에서의 항원의 과발현
Kramer et al. Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine strains
US9115363B2 (en) Gene expression and eradication system in Helicobacter pylori
KR101382215B1 (ko) 마이코박테리움의 일렉트로포레이션 및 마이코박테리움에서항원의 과발현
WU et al. Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector
Hart et al. Stable expression of lentiviral antigens by quality-controlled recombinant Mycobacterium bovis BCG vectors
US8053568B2 (en) Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
WO2009146150A2 (en) Viral recombineering and uses thereof
US20240254167A1 (en) Genetically modified clostridium strains expressing recombinant antigens and uses thereof
Hulbah Development of an Antibiotic Marker-free Gene Delivery System in Streptococcus Gordonii
Nagata et al. 15 Anti-Infective Vaccine Strategies
Schleef P/asmids for Therapy and kchation
Galen et al. Engineering of Attenuated Salmonella enterica Serovars for Use as Live Vector Vaccines
HK1203557A1 (en) Engineered listeria and methods of use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150915